Company profile: DST Diagnostische Systeme
1.1 - Company Overview
Company description
- Provider of in-vitro diagnostic tests and products for allergy and food intolerance, developing, manufacturing and marketing laboratory and point-of-care systems. Offerings include sIgE rapid tests, LIA ALLERGY LINE kits, NutriSMART rapid tests, NutriLAB ELISA kits, over 600 allergen extracts for diagnostic use and IVD manufacturers, and laboratory services with reports and dietary recommendations.
Products and services
- Allergen Extracts: DST fabricates over 600 IVD-grade allergen extracts—respiratory, food, environmental—used in diagnostic tests and incorporated by IVD manufacturers in their products
- Allergy Diagnostics: DST architects in-vitro allergy diagnostics, including sIgE rapid tests and LIA ALLERGY LINE kits that detect specific IgE antibodies to defined allergens for laboratory and Point-of-Care testing
- Food Intolerance Diagnostics: DST delivers ELISA-based food intolerance diagnostics, comprising NutriSMART rapid test and NutriLAB ELISA kits that evaluate specific IgG4 and IgG antibodies against various food allergens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DST Diagnostische Systeme
Dianthus Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapeutics for serious autoimmune diseases, including DNTH103, a long-acting monoclonal antibody that selectively inhibits active C1s in the classical complement pathway. DNTH103 is in Phase 2 for generalized myasthenia gravis, with plans for multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy, using YTE half-life extension for less frequent dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dianthus Therapeutics company profile →
BioXell
HQ: Italy
Website
- Description: Provider of recombinant protein expression and purification services; stable cell line generation using proprietary ExoIN technology and cGMP-compliant CHO-based platforms; transient protein expression; customized protein expression screening; high-yield recombinant protein production in E. coli, yeast, and mammalian systems; and monoclonal and polyclonal antibody development via hybridoma and phage display.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXell company profile →
TxCell
HQ: France
Website
- Description: Provider of cell-based immuno-therapies for severe chronic inflammatory diseases with high medical need, using unique proprietary technology; a spin-off of Inserm based in Sophia Antipolis near Nice, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TxCell company profile →
Aera Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary protein nanoparticle (PNP) delivery platform based on human proteins to deliver genetic medicines across modalities and therapeutic areas, and a therapeutic enzyme platform with novel, compact, programmable gene-editing enzymes to overcome packaging and delivery challenges in gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aera Therapeutics company profile →
Bryn Pharma
HQ: United States
Website
- Description: Provider of nasal-based epinephrine for anaphylaxis, including NDS1C, a needle-free, easy-to-use epinephrine nasal spray for the treatment of anaphylaxis. Also offers a Clinical Development Program focused on demonstrating the pharmacokinetic parameters and safety of NDS1C compared to the 0.3 mg IM epinephrine autoinjector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bryn Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DST Diagnostische Systeme
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DST Diagnostische Systeme
2.2 - Growth funds investing in similar companies to DST Diagnostische Systeme
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DST Diagnostische Systeme
4.2 - Public trading comparable groups for DST Diagnostische Systeme
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →